<?xml version="1.0" encoding="UTF-8"?>
<p>Ibrutinib, acalabrutinib, and venetoclax prolong progression-free and overall survival with lower risk of infections and similar/lower need for hospital care when compared to chemo(immuno)therapy.
 <sup>
  <xref rid="R43" ref-type="bibr">43</xref>–
  <xref rid="R46" ref-type="bibr">46</xref>,
  <xref rid="R54" ref-type="bibr">54</xref>,
  <xref rid="R56" ref-type="bibr">56</xref>,
  <xref rid="R58" ref-type="bibr">58</xref>,
  <xref rid="R59" ref-type="bibr">59</xref>
 </sup> The percentage of opportunistic infections reported for ibrutinib is low (4.1%) and similar to that reported for venetoclax (3.1%).
 <sup>
  <xref rid="R79" ref-type="bibr">79</xref>–
  <xref rid="R82" ref-type="bibr">82</xref>
 </sup> Compared to chemo(immuno)therapy, ibrutinib and acalabrutinib do not produce lymphopenia, a known risk factor for severe COVID-19.
 <sup>
  <xref rid="R79" ref-type="bibr">79</xref>,
  <xref rid="R83" ref-type="bibr">83</xref>–
  <xref rid="R85" ref-type="bibr">85</xref>
 </sup> The incidence of any ≥3 grade adverse events does not differ between ibrutinib (41%–77%), acalabrutinib (50%), and venetoclax (78%), indicating that the frequency of unplanned visits for adverse event management is likely to be similar for the 3 drugs.
 <sup>
  <xref rid="R43" ref-type="bibr">43</xref>–
  <xref rid="R45" ref-type="bibr">45</xref>,
  <xref rid="R54" ref-type="bibr">54</xref>,
  <xref rid="R56" ref-type="bibr">56</xref>,
  <xref rid="R58" ref-type="bibr">58</xref>
 </sup> Venetoclax may require additional unplanned visits for tumor lysis management during the ramp up phase.
</p>
